Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Revenue

In the fiscal year ending June 30, 2026, Prestige Biologics had annual revenue of 26.67B KRW with 112.75% growth. Prestige Biologics had revenue of 14.32B in the quarter ending June 30, 2026, with 151.86% growth. That makes Prestige Biologics the 33,834th largest company in the world by revenue and 2,161st in South Korea.

• Revenue: 26.67B
• Revenue Growth: +112.75%
• P/S Ratio: 3.40
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 90.66B

Revenue Chart

Chart

Chart

Revenue by Segment

• Antibody Drugs 1.48B 68.2%
• Other than Service 689.62M 31.8%

Fiscal year ended Jun 30, 2024 See the full Prestige Biologics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	26.67B	14.13B	112.75%
Jun 30, 2025	12.53B	10.36B	477.83%
Jun 30, 2024	2.17B	423.21M	24.24%
Jun 30, 2023	1.75B	1.73B	11,115.88%
Dec 31, 2022	15.57M	-3.21B	-99.52%

Data Source: S&P Global Market Intelligence Last updated: Aug 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error